RJ Reynolds Ordered to Pay Altria $95 Million in Patent Dispute

Sep.08.2022
RJ Reynolds Ordered to Pay Altria $95 Million in Patent Dispute
RJR ordered to pay Altria over $95 million for patent infringement on Vuse e-cigarette.

In this illustration, a woman is holding a cigarette in front of the Altria logo. Source: Reuters/Dado Ruvic.


On Wednesday, a jury in North Carolina ruled that RJ Reynolds Vapor Co must pay over $95 million to tobacco giant Altria Group after finding that RJR's best-selling Vuse series of e-cigarettes infringed on three of Altria's patents.


Altria, headquartered in Richmond, Virginia, has accused its competitor RJR of infringing on patents related to e-cigarette devices used for storing and heating liquid nicotine pods. Altria is seeking over 5% in royalties on sales of RJR's Vuse Alto device.


Altria announced in a press release that a Greensboro, North Carolina jury accepted its proposed royalty rates when calculating $95.2 million in past damages awarded, and that RJR may be subject to additional ongoing damages following the expiration of its patents in 2035 after post-trial proceedings.


A copy of the verdict cannot be obtained immediately.


A spokesperson for RJR, based in Winston-Salem, North Carolina, expressed disappointment with the ruling and stated that the company will vigorously defend outstanding issues in court and appeal if necessary.


Murphy Gagné, Executive Vice President and General Counsel of Altria, stated that the company is "pleased that the jury recognized the importance of Altria's innovation and the value of its patents.


On Wednesday, a verdict was reached in a case where Philip Morris International won a $10 million judgement in June in Virginia. The company accused RJR of infringing on two e-cigarette patents with their Vuse Solo and Alto devices.


RJR has filed a lawsuit against Philip Morris and Altria in Virginia, alleging that Philip Morris' IQOS heated tobacco device infringes on its e-cigarette patents. Last November, RJR won an order to block the importation of IQOS from the International Trade Commission.


Statement:


This article is compiled from third-party information and is intended for industry-related communication and education purposes only.


This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS is not able to confirm the authenticity or accuracy of the article's content. The translation of this article is intended only for industry-related communication and research.


Due to limitations in the compilation ability, the compiled article may not fully convey the original expression. Please refer to the original text for accuracy.


2FIRSTS is completely aligned with the Chinese government in regards to any domestic, Hong Kong, Macao, Taiwan, or foreign issues and positions.


The copyright of compiled information belongs to the original media and author, and if there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Researchers at the Chinese Academy of Sciences reconstructed nicotine biosynthesis in non-tobacco plants and yeast systems, highlighting how advances in synthetic biology could gradually reshape future nicotine production technologies and challenge regulatory frameworks built around tobacco-derived definitions.
Special Report
May.07
BAT AGM Highlights Smokeless Strategy, AI Capability and Regulatory Engagement
BAT AGM Highlights Smokeless Strategy, AI Capability and Regulatory Engagement
BAT Chair Luc Jobin told shareholders at the company’s 2026 Annual General Meeting that BAT delivered on its plans in 2025 despite a challenging external environment, with the U.S. business returning to growth, smokeless consumers increasing by more than 15%, improved New Categories contribution, and GBP 6.3 billion returned to shareholders.
Apr.16 by 2FIRSTS.ai
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International announced on April 20 that IQOS has partnered with French acoustic engineering company Devialet to launch “Soundsorial Design” at Milan Design Week 2026. The collaboration includes an immersive exhibition and a limited-edition product set named “Soundsorial.” The exhibition will run from April 20 to April 27 at Opificio 31 in Milan.
Apr.22 by 2FIRSTS.ai
Philip Morris Says Its Smoke-Free Transition in Spain Now Has Economic Impact Above EUR 3.3 Billion
Philip Morris Says Its Smoke-Free Transition in Spain Now Has Economic Impact Above EUR 3.3 Billion
Philip Morris said it is accelerating its transition toward smoke-free products in Spain and claimed that the related economic impact now exceeds EUR 3.3 billion. Philip Morris also said that more than 90% of nicotine consumption in Spain still comes from conventional cigarettes, leaving room for growth in smoke-free categories, while regulation and taxation remain major obstacles in its view.
Apr.21 by 2FIRSTS.ai
Geneva Court Annuls Ban on Disposable E-Cigarette Sales, Says Power Lies With Federal Authorities
Geneva Court Annuls Ban on Disposable E-Cigarette Sales, Says Power Lies With Federal Authorities
The Geneva Court of Justice on Tuesday upheld appeals filed by four associations and companies active in the tobacco trade and annulled the Geneva legal provision banning the sale of disposable e-cigarettes, commonly known as “puffs.”
Apr.30 by 2FIRSTS.ai
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai